Ketorolac: Nursing Drug Guide, 5-Day NSAID Limit & GI Bleeding

Ketorolac tromethamine is available generically and was widely known as Toradol (IV/IM injection and oral tablets). Ophthalmic ketorolac (e.g., Acular) is a different formulation—do not confuse systemic orders with eye drops.

Do not confuse ketorolac with other NSAIDs (ibuprofen, naproxen, indomethacin, or meloxicam) when reconciling therapy. Ketorolac is contraindicated with concurrent NSAID or aspirin use—duplicate NSAID orders are never acceptable.

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (up to five days in adults) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting per labeling. Therapy should be initiated with IV or IM ketorolac; oral ketorolac is indicated only as continuation after IV/IM dosing if necessary. It is not indicated for minor or chronic painful conditions. Nurses must track cumulative therapy days across routes and transition patients to alternative analgesics (e.g., acetaminophen or morphine per prescriber plan) before the five-day limit is exceeded.

↔On a small screen, swipe or scroll sideways to see the full table.

Ketorolac inhibits cyclooxygenase, reducing prostaglandin-mediated pain and inflammation. It is a potent NSAID with strong antiplatelet activity and boxed warnings for serious GI bleeding and cardiovascular thrombotic events. Adverse reaction rates increase with higher doses; exceeding recommended duration or daily maximum does not improve efficacy but increases harm per labeling. Ketorolac is eliminated primarily by the kidneys—use caution with furosemide, ACE inhibitors, or ARBs that reduce renal perfusion.

Use the lowest effective dose for the shortest duration—and never exceed five total days of combined IV/IM and oral ketorolac in adults. Verify indication, therapy day count, renal function, weight, age, bleeding risk, and confirm no concurrent aspirin or NSAID before administration. Oral ketorolac is continuation therapy only after IV/IM dosing.

Breakthrough pain: Do not increase ketorolac dose or frequency beyond labeling—consider supplemental opioid PRN per prescriber when ketorolac alone is insufficient.

Missed dose: If a scheduled dose is missed, follow institutional policy; do not double doses or extend therapy beyond five days without prescriber and pharmacy review.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Perform medication reconciliation—screen for duplicate NSAIDs, aspirin, anticoagulants, ACE inhibitors, ARBs, and diuretics
• Review allergy history: ketorolac, aspirin/NSAID reactions, aspirin-sensitive asthma, prior serious NSAID skin reactions
• Assess cardiovascular history, blood pressure, edema, renal function (BUN/creatinine), and prior GI bleeding or peptic ulcer disease
• Confirm surgical plan—hold per protocol before CABG; NSAIDs are contraindicated for CABG pain

Contraindications

• Known hypersensitivity to ketorolac; previous serious skin reactions to NSAIDs (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) per labeling
• History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs (including aspirin-sensitive asthma / aspirin triad)
• Active peptic ulcer disease, recent GI bleeding or perforation, or history of peptic ulcer disease or GI bleeding
• Advanced renal impairment or risk for renal failure due to volume depletion
• Patients currently receiving aspirin or other NSAIDs; concomitant probenecid or pentoxifylline
• CABG surgery; prophylactic analgesia before major surgery; labor and delivery
• Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding
• Epidural or intrathecal administration (alcohol in injection formulation)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

IV: Administer IV bolus over no less than 15 seconds per injection labeling. Do not give epidural or intrathecal—alcohol in formulation contraindicates neuraxial use.

IM: Inject slowly and deeply into muscle.

Oral: Use only as continuation after IV/IM when ordered; tablets are not indicated in pediatric patients per labeling.

• Confirm no aspirin, ibuprofen, naproxen, or other NSAID on MAR or home list after reconciliation
• Document therapy day number (1–5) on each administration record
• Document indication, dose, route, time, and pain score before and after doses
• After day 5 or earlier if pain controlled, notify prescriber to transition to non-NSAID analgesia per protocol

• Improved pain score after IV/IM dosing—analgesic effect often begins in ~30 minutes with maximum effect in 1–2 hours per labeling
• Duration of analgesia usually 4–6 hours, supporting q6h dosing within daily maximum
• No GI bleeding, hypotension, oliguria, rising creatinine, or surgical-site bleeding while therapy continues
• Plan to transition to non-NSAID analgesia before the five-day combined limit is reached

Hold ketorolac and escalate immediately when serious NSAID complications are suspected.

• Black stool, hematemesis, coffee-ground emesis, or severe abdominal pain suggesting GI bleeding
• Chest pain, sudden weakness, facial droop, slurred speech, or other stroke or MI symptoms
• New or worsening dyspnea, rapid weight gain, or peripheral edema in patients with heart failure
• Decreased urine output, rising creatinine, or hyperkalemia suggesting acute kidney injury
• Severe headache persisting despite dose reduction, new confusion, psychosis, or somnolence impairing safety
• Urticaria, facial swelling, wheezing, or anaphylaxis after a dose
• Jaundice, dark urine, or persistent nausea with rising AST/ALT on liver function tests

↔On a small screen, swipe or scroll sideways to see the full table.

Symptoms following acute NSAID overdosage have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care per ketorolac labeling. GI bleeding can occur; hypertension, acute renal failure, respiratory depression, and coma have occurred but were rare. Because ketorolac is highly protein bound, hemodialysis or hemoperfusion may not be useful.

Management

• No specific antidote—provide symptomatic and supportive care
• Consider emesis, gastric lavage, or activated charcoal for recent large ingestions per NSAID overdosage guidance in labeling
• Monitor airway, breathing, renal function, GI bleeding, and blood pressure
• Discontinue ketorolac and avoid other NSAIDs during management

• Ketorolac vs ketoprofen / ketoconazole—similar “keto-” prefixes; read back full generic name on verbal orders
• Toradol vs tramadol—sound-alike postoperative analgesics with very different risk profiles
• Systemic vs ophthalmic ketorolac—Acular eye drops are not interchangeable with IV/IM Toradol orders
• IV push rate—never rapid IV bolus; minimum 15-second administration per labeling
• Duplicate NSAID therapy—ketorolac plus scheduled ibuprofen or home naproxen is contraindicated, not merely discouraged

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Pain and function using structured pain assessment and mobility goals
• GI status—stool color, hemoglobin trend, and symptoms of bleeding or ulcer
• Blood pressure, weight, edema, and heart failure symptoms
• Renal function and electrolytes on BMP when diuretics, ACE inhibitors, or ARBs are co-administered
• INR and bleeding signs when anticoagulants are used
• Mental status, headache, dizziness, and fall incidents—especially in older adults
• CBC and chemistry when ketorolac continues beyond 48 hours or renal risk factors present or hepatic risk factors are present per labeling

Document

• Dose, route, time, indication, and pain score response for acute postoperative pain or PRN doses
• Allergy verification (NSAID, aspirin-sensitive asthma, prior serious skin reaction)
• Patient education on five-day limit, duplicate NSAID prohibition, bleeding signs, and when to seek urgent care
• Hold parameters communicated to patient and on the MAR per institutional policy

• Ketorolac is for short-term severe pain only—you should not receive it for more than five days total
• Do not take ibuprofen, naproxen, aspirin, or other NSAIDs while on ketorolac unless your prescriber explicitly directs you to
• Report black or bloody stools, vomiting blood, severe stomach pain, chest pain, shortness of breath, unusual bruising, decreased urine output, or surgical wound bleeding immediately
• Tell all clinicians you received ketorolac before surgery, dental work, or new prescriptions
• Pregnancy: avoid NSAIDs after about 30 weeks; tell your clinician if you are pregnant or breastfeeding
• Discard unused ketorolac at discharge—do not save “leftover” NSAID tablets for home use beyond the prescribed short course

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for ketorolac using a tabbed postoperative case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, ordered escalation steps, documentation cloze, and matrix urgency sorting—track the five-day limit → analyse duplicate NSAID risk → prioritise holds → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.